Skip to Main Content

Paper Details

A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Neuro Oncol
15
2022
ALDH, Cas9, Group, Group 3 MB cell lines, MB, MB tumor, MYC, MYC-driven medulloblastoma, Medulloblastoma, Onvansertib, PCM-075, PLK1, RNA, cancer, genes, medulloblastoma, onvansertib, patient, stem cell, tumor
Author NameAffiliation
Nicholas K ForemanUniversity of Colorado Anschutz Medical Campus
Nicholas K ForemanUniversity of Colorado Denver
Nicholas K ForemanMorgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado
Sujatha VenkataramanUniversity of Colorado Anschutz Medical Campus
Sujatha VenkataramanMorgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado
Rajeev VibhakarUniversity of Colorado Anschutz Medical Campus
Rajeev VibhakarMorgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado
Rajeev VibhakarUniversity of Colorado Denver
  • 1 - 8

Datasets

Release 1.2